Release date: 2017-06-22 Founded in 1940, the American Diabetes Association (ADA) is a non-profit health organization with nearly 14,000 members. It aims to promote the development of diabetes research, education, and diagnostic technology by providing research and information about diabetes. To achieve the goal of preventing and treating diabetes and improving the quality of life of diabetic patients. The ADA Science Conference has been held for 77 sessions and is the largest and most important diabetes conference in the world. The 77th American Diabetes Association Scientific Conference has just ended on June 13. The participating researchers and medical professionals shared current advances in diabetes research, treatment and care, as well as more than 3,000 original research reports. Diabetes management is a key area of ​​research and development for many digital healthcare companies. Large medical device companies in the United States, such as Medtronic and DexCom, are also increasingly investing in smartphone applications and consumer-grade connected devices. So at this year's ADA conference, technology and digital healthcare companies showed potential that could not be ignored. Arterial Network (WeChat: vcbeat) compiled and compiled reports on foreign media MobileHealthNews, especially the latest results released by various digital medical companies, to give you a glimpse of the advances in digital medicine in the field of diabetes. DexCom: Apple Local Bluetooth, Android App and AGP Report Dekcom Medical (DexCom) was founded in 1999 and is headquartered in San Diego, California. With 1212 full-time employees, the company is a medical device company focused on the design, development and commercialization of blood glucose monitoring systems. Since the beginning of June, DexCom has frequently released new news on its leading dynamic blood glucose monitor (CGM). First on June 5th, DexCom announced at Apple's WWDC that it would be one of the first companies to be able to connect directly to Apple Watch using local Bluetooth. Previously, Dekang had provided Apple Watch applications for its CGM users, but people still need to put the paired Apple phones within the Bluetooth range, which reduces the convenience. Now CGM will be able to connect directly to the watch. Then, on June 7, DexCom announced the launch of the long-awaited Android app Dexcom Share. The app has just received FDA approval and will be available to Android users this month. At the ADA conference, DexCom also announced an update to the company's diabetes management software platform CLARITY. DexCom is working with the International Diabetes Center (IDC) to integrate the Ambulatory Glucose Profile (AGP) report developed by IDC into the platform. Dr. George Grunberger, Chairman of the Grunberger Diabetes Institute, is very optimistic about this cooperation. He believes that AGP's report has been used in clinical practice for several years, providing the most relevant statistical and graphical information, enabling clinicians to quickly assess patients' glycemic control levels and make meaningful clinical decisions. . If the equipment of a medical device company is compatible with such information, the utility of the device can be greatly improved. According to this trend, AGP is expected to become an "ECG report" in the field of diabetes, which can be used worldwide. One Drop: Amazon Alexa Voice Assistant Jeff Dachis, founder of One Drop, is a senior technology worker with 20 years of experience in the technology field. He founded Razorfish and Dachis Group. Due to his own type 1 diabetes, Dachis founded One Drop in 2015 to provide users with a consumer-grade blood glucose monitoring kit. The core component of the kit is an FDA-approved meter that can transfer data to the One Drop Mobile APP via Bluetooth (with iPhone and Apple Watch). In addition, the kit is equipped with a blood collection device that includes 10 needles and 100 test strips. Currently, One Drop adds a powerful feature to its subscribers: integrating Amazon's Alexa voice assistant into the app. Users don't need to enter any information manually, they can use voice to let Alexa track blood sugar, food and physical activity in the One Drop app. According to Jeff Dachis, accessibility is the foundational value of One Drop. Now, by adding new voice and alternative visual interfaces, the team is realizing this commitment to visually/tactile interfaces for people with visual impairments, neuropathy or flexibility, older people, caregivers, and smartphones. People with disabilities can successfully use diabetes care services. In addition, One Drop currently offers two new diabetes education and mentoring programs: “How to deal with chronic illness and burnout†and “Advanced carbohydrate meteringâ€. Medtronic: Update of MiniMed and SmartGuard insulin pumps and SugarIQ Headquartered in Minneapolis, Minnesota, USA, Medtronic is a leading global medical technology company with nearly 70 years of history, dedicated to providing more advanced and convenient solutions for patients with chronic diseases. In this ADA meeting, Medtronic published several research results covering the clinical effectiveness of the device and how machine learning affects personalized diabetes management. Medtronic highlights the insulin pump treatment performance of its MiniMed and SmartGuard systems, as well as an update to the SugarIQ application that the company developed in collaboration with IBM Watson last year. SugarIQ interface screenshot The app creates food logs manually and integrates data from MiniMed Connect. When users record information about the food they eat, the time they use insulin, and their blood sugar levels, Watson Machine Learning will generate a predictive report based on the data entered. In addition, Medtronic will also delve into notification and engagement strategies, such as email notifications for outpatient and family disease management. T1D Exchange&Admetsys: Collaboration to develop an automated insulin delivery system The Boston-based T1D Exchange is a non-profit organization focused on driving innovation and research in the treatment of type 1 diabetes. Currently, the agency is working with Admetsys, an artificial pancreas technology provider. Although the specific terms of the cooperation between the two have not been disclosed, there is news that T1D Exchange will work with Admetsys to develop the Admetsys Automatic Insulin Delivery (AID) system for clinical use in hospitals. This technique has been used in three clinical trials to measure blood glucose levels every few minutes using the IV standard and then return the blood to the patient. Based on the measured blood glucose values, Admetsys created a computational model to guide the insulin dose of the syringe pump. Glooko: Clinical research proves mobile application effects Glooko, a diabetes data management platform, detailed two retrospective studies at the ADA meeting. The study showed that Glooko's mobile app reduced the average blood glucose level, glycosylated hemoglobin and hyperglycemia in diabetic patients. In addition, the mobile application group also had more blood glucose tests than the control group. The average blood glucose reduction rate in the mobile application group was 3.54%, and the probability of suffering from high blood sugar was reduced by 4.38%. Glooko CEO Rick Altinger said that it is a pleasure to see clinical evidence that Glooko can have a positive impact on people with diabetes. Glooko is committed to making diabetes treatment easier through digital tools, thereby improving the clinical outcomes of people with diabetes. “We have always had good user satisfaction, and this type of clinical evidence will greatly increase investor confidence in digital healthcare companies' efforts to improve the lives of people with chronic conditions.†Ascensia & Voluntis: Interconnected Blood Glucose Meter + Insulin Management App Ascensia was created by Panasonic Medical Group after the acquisition of Bayer Diabetes Care last year and is currently working with Voluntis, an application manufacturer based in Paris, France. Ascensia received FDA approvals for two interconnected blood glucose meters, Contour Next One and Contour Next Link, and Voluntis is developing an app called Insulia Diabetes Management Companion for Type 2 Diabetes. Ascensia's blood glucose meter will connect to the Voluntis app via Bluetooth and use the blood glucose reading to calculate the dose of insulin administered. According to Michael Kloss, CEO of Ascensia, type 2 diabetes is a complex condition, especially for people who use insulin for insulin injections as part of their daily management of diabetes. Through collaboration with Voluntis, Ascensia is better able to help patients with type 2 diabetes manage insulin therapy. This is our first partner in the field of drug management because Voluntis' technology is an important part of integrated diabetes management. DarioHealth: Launching a charity donation program Israel's connected blood glucose meter company DarioHealth did not launch new products or features at the conference, but announced a new charity initiative called DarioCares: DarioHealth will donate a portion of its proceeds for charities working in the diabetes field and non-profit organization. Chairman and CEO Erez Raphael said that the ADA conference is the largest annual event in the diabetes industry, where many NGOs gather. “We look forward to strengthening relationships with them through DarioCares, increasing awareness of diabetes in society, promoting the transformation of people with diabetes, and making a greater contribution to the diabetes community.†MedAngel: Achieve patient monitoring of drug temperature Like the One Drop mentioned earlier, the founder of digital medical company MedAngel is also a type 1 diabetic. The company introduced a temperature-controlled product at the ADA to monitor the temperature of temperature-sensitive drugs such as insulin. The full suite includes a wireless temperature sensor that is placed with the drug, as well as an iOS and Android app that sends a reminder notification to the user when the temperature of the drug storage is out of safe range. Laura Kr?mer, a pharmacist at the MedAngel team, said that initially they just wanted to address a very practical concern for drug users about drug storage, but then they realized that temperature control is a key part of whether a drug can guarantee quality. In the entire delivery chain of drugs, suppliers and pharmacies perform thorough temperature monitoring, but once the drug is delivered to the patient, it is often difficult to continue to control the temperature, resulting in people often have to throw away expensive drugs because of improper storage. Cause unnecessary waste. The company's wireless sensors are available for $49 on Amazon and MedAngel's website. Reference material Http:// Https://professional.diabetes.org/meeting/scientific-sessions/77th-scientific-sessions Note: The interview data appearing in the article is provided and confirmed by the respondent. Source: Arterial network (micro signal: vcbeat) NINGBO YOUHE MOTHER&BABY PRODUCTS CO.,LTD , https://www.oembreastpump.com